Share on StockTwits

GlaxoSmithKline plc (NYSE:GSK) has been given an average rating of “Hold” by the twenty brokerages that are currently covering the stock, reports. Three analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $52.67.

GSK has been the subject of a number of recent research reports. Analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, August 22nd. Separately, analysts at Argus cut their price target on shares of GlaxoSmithKline plc from $65.00 to $55.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. Finally, analysts at Galvan Research reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th.

GlaxoSmithKline plc (NYSE:GSK) opened at 48.87 on Monday. GlaxoSmithKline plc has a one year low of $46.01 and a one year high of $56.73. The stock has a 50-day moving average of $49.42 and a 200-day moving average of $53.1. The company has a market cap of $117.4 billion and a price-to-earnings ratio of 15.16.

GlaxoSmithKline plc (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 23rd. The company reported $0.65 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.71 by $0.06. On average, analysts predict that GlaxoSmithKline plc will post $3.24 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, October 2nd. Investors of record on Friday, August 8th will be given a dividend of $0.6482 per share. This represents a $2.59 dividend on an annualized basis and a yield of 5.31%. The ex-dividend date of this dividend is Wednesday, August 6th.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Receive News & Ratings for GlaxoSmithKline plc (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.